Is TB-500 Safe? Side Effects, Cancer Cautions and What Is Not Known

Thymosin beta-4 is a 43-amino-acid protein found in almost every human cell and in blood, tears, saliva and wound fluid. TB-500 is a synthetic seven-amino-acid fragment of it, amino acids 17 to 23, with an acetyl group on the first amino acid: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln. That segment contains the actin-binding region of the parent protein, which is why it was chosen. Most of the research cited for TB-500, including nearly everything about mechanism, was done on full-length thymosin beta-4. The FDA's briefing says so directly: several websites use the two names interchangeably, but "thymosin beta-4 and TB-500 are not the same substance." The human tolerability data that exists, all on the parent protein, is therefore supportive but not directly transferable. What TB-500 is covers the biology.

The parent protein has been studied in animals for more than twenty-five years. The Journal of Investigative Dermatology in 1999 reported faster dermal wound closure in rats; Wound Repair and Regeneration in 2003 extended that to diabetic and aged mice; Mechanisms of Ageing and Development in 2004 described angiogenesis, wound repair and hair-follicle effects. Nature in 2007 reported epicardial progenitor mobilisation in the adult mouse heart, and Cardiovascular Research in 2023 cardiac regeneration after ischaemic injury in mice. The corneal work in Experimental Eye Research (2002, 2007) and Current Eye Research (2002) describes faster epithelial healing after chemical injury.

Treated animals are not described as developing toxicity, and the reviews in Trends in Molecular Medicine (2005) and Annals of the New York Academy of Sciences (2010) both characterise the protein as well tolerated. What the literature lacks is a toxicology programme for the fragment. The FDA's July 2026 review identified no nonclinical toxicity, developmental, reproductive or carcinogenicity studies of TB-500 in either its free-base or acetate form. The only in-vivo pharmacokinetics FDA found were in thoroughbred horses: after a subcutaneous dose, plasma levels peaked within one to two hours and were unquantifiable within six to ten hours, the peptide being broken into shorter acetylated fragments. That comes from a 2012 Journal of Chromatography A paper written to detect TB-500 in racehorses, not to establish its safety.

A 2024 study in the Journal of Chromatography B measured TB-500 and its metabolites in rats and screened them in a fibroblast scratch assay. At the single concentration tested, TB-500 itself did not close the in-vitro wound, whereas one of its shorter metabolites did; the FDA cited this as showing that whether TB-500 acts directly or through a metabolite is unknown. One cell assay without a dose-response curve settles nothing, but it is a reminder that "TB-500 does what thymosin beta-4 does" is an assumption. The 2026 rat Achilles study in Joint Diseases and Related Surgery, examining BPC-157 and TB-500 histologically and biomechanically, is one of very few animal experiments to use the fragment itself.

There are no randomised human trials of TB-500. That sentence needs to stand on its own, because marketing blurs it.

What does exist are human studies of full-length thymosin beta-4, run by the company that developed it as an investigational drug. Annals of the New York Academy of Sciences in 2010 reported a randomised, placebo-controlled single- and multiple-dose study of intravenous thymosin beta-4 in healthy volunteers, described as well tolerated with no dose-limiting adverse events. The same journal in 2012 summarised dermal-healing trials in pressure ulcers, venous stasis ulcers and epidermolysis bullosa, again describing the treatment as safe in those small studies. Cornea in 2015 reported a phase 2 randomised trial of thymosin beta-4 eye drops in severe dry eye, and Archives of Ophthalmology in 2010 a small series in non-healing corneal defects.

Those trials show that the parent protein, given intravenously for days or topically for weeks, did not cause obvious harm. They say nothing about a synthetic fragment injected subcutaneously for months. The FDA searched PubMed, Embase and ClinicalTrials.gov and found no clinical study or human exposure data for TB-500 by any route.

The FDA's Office of Surveillance and Epidemiology searched the FDA Adverse Event Reporting System for TB-500 through 26 March 2025 and retrieved no reports, and a literature search found no published case reports of adverse events. A search of the Human Foods complaint system found two complaints about a blended TB-500 and BPC-157 product, neither including a safety assessment. An empty database is genuinely reassuring, but the FDA adds that reporting is voluntary, that it does not receive all reports, especially for compounded products, and that it therefore "cannot make definitive conclusions regarding the safety of TB-500."

Beyond that sits a decade of prescribing by sports-medicine, orthopaedic and longevity clinics, usually alongside BPC-157, describing a consistent and mostly mild side-effect pattern. Clinical experience is real evidence, but it is unblinded and unrecorded: it detects common short-term effects well and rare or delayed effects poorly.

This is the caution people search for, and it deserves a precise answer rather than reassurance or alarm.

The concern is mechanistic. Thymosin beta-4 is described as promoting cell migration (FASEB Journal 1997 reported directional migration of human endothelial cells), angiogenesis (Mechanisms of Ageing and Development 2004), and matrix metalloproteinase expression during wound repair (Journal of Cell Physiology 2006). Each is also a process a growing tumour relies on. There is oncology research on the parent protein too. The Journal of the National Cancer Institute published a 2003 review titled, plainly, "Role of thymosin beta4 in tumor metastasis and angiogenesis." The American Journal of Pathology in 2002 reported that thymosin beta-4 expression regulated motility and metastasis in malignant mouse fibrosarcoma cells. Oncogene in 2003 reported that overexpressing the gene in a human colon cancer cell line was associated with more malignant behaviour, and Oncogene in 2007 described thymosin beta-4 triggering an epithelial-to-mesenchymal transition in colorectal carcinoma cells through integrin-linked kinase.

So the research shows, consistently, that thymosin beta-4 is a protein many tumours express at high levels and that, inside cancer cells, it is associated with the machinery of invasion and spread.

What the research does not show is that giving thymosin beta-4 or TB-500 to a person or an animal causes a new cancer or accelerates an existing one. No such study exists in either direction. The studies above measure what cancer cells do with the protein they already make; they do not administer it to a whole organism and watch for tumours. The FDA confirms that no carcinogenicity study of TB-500 has been done, which is an absence of evidence, not evidence of harm. The healthy-volunteer and dry-eye trials of the parent protein were too short and too small to detect a cancer signal.

The reasonable position, and the one Pepti's physicians take, is asymmetric. For someone with no cancer history, there is no observed human signal and the theoretical concern is weighed against the benefit sought. For someone with active or recent cancer, the mechanism is close enough to what a tumour needs that the peptide is declined, because "no evidence of harm" is not "evidence of no harm" and the downside is not one to test on yourself. The general reasoning is in can peptides cause cancer.

The concern the FDA's July 2026 briefing returns to most often is not cancer; it is immunogenicity. Any peptide given by injection can generate antibodies against itself, and the FDA describes subcutaneous injection, the usual route for TB-500, as more immunogenic than intramuscular or intravenous administration. Two things make it worse: aggregation, where peptide molecules clump into larger structures the immune system is more likely to notice, and peptide-related impurities from synthesis.

The consequences range from antibodies that do nothing, to an allergic reaction, to antibodies that neutralise the peptide so it stops working, to, in principle, antibodies that cross-react with your own thymosin beta-4. The FDA found no clinical study assessing immunogenicity or aggregation of TB-500. The empty adverse-event record argues that clinically important reactions are rare, but the risk is uncharacterised, which is why the quality of the finished vial matters: impurity profile, aggregate, sterility and bacterial endotoxin testing are exactly what a licensed pharmacy's certificate of analysis addresses and a research-chemical vendor's does not. Pepti's pharmacy testing is described at /quality and the results at /quality/lab-results.

New vessel growth is one of the two mechanisms behind the cancer caution, but it has a more mundane relevance too. Cell and animal work describes thymosin beta-4 promoting endothelial migration and vessel formation, and Nature in 2004 reported it activating integrin-linked kinase in cardiac cells. For someone on anticoagulants or antiplatelet drugs the interaction is untested rather than known to be dangerous, which is why the full medication list is reviewed by a physician rather than a checkbox. Unexplained bleeding or bruising away from injection sites is a stop-and-report symptom.

The FDA raises a risk that has nothing to do with pharmacology. "TB-500" is a common name, not a United States Adopted Name, and the FDA reports encountering multiple salts and derivatives, including different active moieties, sold under that one label; its stated concern is that a patient may be dosed with a different substance than the physician intended. The safety literature above is about one specific heptapeptide; it says nothing about whatever an unlabelled "TB-500" from an unaccountable source contains. This is the risk the opening paragraph refers to, and the one most people taking TB-500 are actually carrying. See research peptides vs prescription peptides.

TB-500 is not a growth hormone secretagogue and does not act on the pituitary, so the growth-hormone cautions that apply to some peptides do not apply to it. They do apply to REVIVE, which pairs TB-500 with CJC-1295 and ipamorelin; anyone prescribed REVIVE also takes on the considerations of a GH-releasing pair, including IGF-1 and glucose monitoring. Likewise TB-500 on its own carries no copper load, but GLOW and KLOW pair it with GHK-Cu, a copper-binding peptide, and the copper considerations on the GHK-Cu page are part of what a physician weighs before prescribing GLOW or KLOW rather than TB-500 by itself.

TB-500 is not a component of any FDA-approved drug, and there is no USP monograph for it. Compounded medications are never FDA approved as finished products; the pharmacy prepares them against a prescription rather than seeking approval. Every product on this page falls into that category, as explained in are peptides FDA approved.

On the FDA's 503A bulk drug substances list, updated 14 May 2026, TB-500 and thymosin beta-4 do not appear in any of the three categories. Category 2, the substances the FDA has flagged as raising significant safety risks, currently contains six: cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10 and quinacrine for intrauterine use. TB-500 is not among them.

On 23 and 24 July 2026 the FDA's Pharmacy Compounding Advisory Committee met to consider seven peptides for the 503A Bulks List, the positive list of substances pharmacies may compound. TB-500, in free-base and acetate forms, was on the 23 July agenda for the proposed use of wound healing.

The FDA's own scientists recommended against adding it. Their briefing concluded that the substance is not well characterised chemically, that its history of use in compounding is unclear, that there is no evidence of effectiveness in humans, and that "potential safety risks associated with the use of these substances in humans are unknown," with immunogenicity the particular concern.

The committee disagreed. It voted 8 in favour, 6 against, with 1 abstention, to recommend adding TB-500 to the 503A Bulks List, the same margin by which it recommended BPC-157 and KPV.

An advisory committee recommends; it does not decide. The FDA will not issue a final determination until the committee's input and its own reviews are complete, and adding a substance to the Bulks List requires notice-and-comment rulemaking, which the McDermott summary notes could occur in 2027 or extend over several years.

So the accurate description in September 2026 is: not FDA approved, not flagged on Category 2, recommended for the positive list by the advisory committee against the FDA staff position, and awaiting final agency action. What a committee vote cannot do is create human safety data. The scientists weighted the absence of human data and the immunogenicity question; the committee majority evidently weighted the long history of use without an adverse-event signal. Neither side claimed TB-500 had been shown to be harmful; the disagreement was about how much weight an absence of evidence should carry, and a patient deciding whether to take it is making the same judgment with a physician who knows their history.

The 2026 World Anti-Doping Code Prohibited List, in effect from 1 January 2026, lists "Thymosin-ß4 and its derivatives e.g. TB-500" by name under S2.3, growth factors and growth factor modulators. Section S2 is prohibited at all times, in and out of competition. A prescription does not change that; only a therapeutic use exemption would, and those require an approved indication that TB-500 does not have. It is also detectable: TB-500 was marketed for horses and racing greyhounds from 2011, and the Journal of Chromatography A published a validated method for finding it in equine urine and plasma in 2012. A tested athlete should assume it will be found.